HY
Therapeutic Areas
Burning Rock Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LungPlasma | Therapy selection for Non-Small Cell Lung Cancer (NSCLC) | Approved |
| OncoScreen Plus / 6-Gene Panel | Therapy selection for solid tumors (via tissue) | Approved |
| ELSA-seq / OverC™ Multi-Cancer Detection Blood Test | Multi-Cancer Early Detection (MCED) | Clinical Validation |
| MRD Assays | Minimal Residual Disease monitoring for solid tumors (e.g., Lung, Colorectal) | Clinical Validation |
Leadership Team at Burning Rock Biotech
Y(
Yusheng (Shawn) Han
Founder, Chairman and Chief Executive Officer
LL
Leo Li
Chief Financial Officer
ZZ
Zhang Zhe
Chief Technology Officer
S(
Simon (Xiaobin) Lu
Chief Medical Officer
DT
Dechao Tang
Director
D(
David (Xiaodong) Wang
Independent Director
JZ
Jian Zhang
Independent Director